布地奈德吸入剂及其联合口服缓释茶碱治疗支气管哮喘的效果  

Effects of therapy of Budesonide powder for inhalation combined with Theophylline on bronchial asthma

作　　者：刘广杰[1] 胥杰[1] 罗秀芳[1] 

机构地区：[1]首都医科大学附属北京同仁医院呼吸内科,北京100730

出　　处：《中国医药导报》2015年第18期12-15,共4页China Medical Herald

基　　金：教育部留学回国人员科研启动基金资助项目

摘　　要：目的：探讨布地奈德干粉吸入剂联合茶碱在支气管哮喘治疗中的效果及安全性。方法收集2011年1月~2014年12月于首都医科大学附属北京同仁医院门诊就诊的支气管哮喘患者76例,分为布地奈德干粉吸入剂组（玉组）37例和布地奈德吸入剂和茶碱联合用药组（Ⅱ组）39例。观察哮喘控制测试评分（ACT）、检测肺功能、药物不良反应,评估Ⅰ、Ⅱ组治疗前后效果。结果治疗后Ⅰ、Ⅱ组患者的临床症状均得到明显改善,两组治疗后哮喘控制率（Ⅰ组：86.5%,Ⅱ组：97.4%）、ACT评分[Ⅰ组：（23.2±3.2）分,Ⅱ组：（24.3±1.6）分]、最大呼气流量占预计值的百分比（PEF%预计值）[Ⅰ组：（88.3±6.9）,Ⅱ组：（95.2±7.8）%]、第1秒用力呼气容积占预计值的百分比（FEV1%预计值）[Ⅰ组：（78.2±6.0）%,Ⅱ组：（83.9±6.0）%],分别较治疗前各指标[哮喘控制率：Ⅰ组18.9%、Ⅱ组17.9%,ACT评分：Ⅰ组（15.9±3.2）分、Ⅱ组（16.0±3.2）分,PEF%预计值：Ⅰ组（70.1±6.6）%、Ⅱ组（68.9±6.8）%,FEV1豫预计值：Ⅰ组（68.1±6.4）%、Ⅱ组（69.1±5.4）%]明显改善,差异均有高度统计学意义（P〈0.01）。治疗后,Ⅱ组哮喘控制率高于Ⅰ组,差异有统计学意义（P〈0.05）；Ⅱ组肺功能指标PEF豫预计值、FEV1豫预计值均优于Ⅰ组,差异均有高度统计学意义（P〈0.01）。两组在治疗中均无严重不良反应发生。结论布地奈德干粉吸入治疗和布地奈德干粉吸入剂联合茶碱治疗哮喘均具有良好的效果和安全性,且布地奈德干粉吸入剂和茶碱联合治疗的疾病控制率更高,改善病情更快,疗效更好。Objective To explore the therapeutic efficacy and therapy safety of Budesonide powder for inhalation com-bined with Theophylline on bronchial asthma. Methods From January 2011 to December 2014, in Outpatient Service of Beijing Tongren Hospital, Capital Medical University, 76 bronchial asthma patients were divided into Budesonide pow-der for inhalation group （groupⅠ） with 37 patients and Budesonide powder for inhalation combined with Theophylline group （group II） with 39 patients. Asthma control test （ACT） scores, lung function （PEF%pre, FEV1%pre） and adverse drug reaction were observed, effect before and after the treatment were evaluated. Results Aftertreatment, clinical symptoms of patients in two groups were improved significantly, the ratio of asthma control （groupⅠ：86.5%, group II：97.4%）, ACT scores [groupⅠ：（23.2±3.2） scores, groupII：（24.3±1.6） scores], PEF% pre [groupⅠ：（88.3±6.9）%, groupII： （95.2±7.8）%], FEV1% pre [group Ⅰ： （78.2±6.0）%, group II： （83.9±6.0）%] were improved significantly than those before the treatment [ratio of asthma control：groupⅠ18.9%, groupII17.9%;ACT scores：groupⅠ （15.9±3.2） scores, group II （16.0±3.2） scores, PEF%pre group Ⅰ （70.1±6.6）%, group II （68.9±6.8）%; FEV1%pre： group Ⅰ （68.1±6.4）%, groupII （69.1±5.4）%], the differences were statistically significant （P〈0.01）. After the treatment, ratio of asthma con-trol in group II was higher than that in group Ⅰ, the difference was statistically significant （P 〈 0.05）; PEF%pre, FEV1%pre in groupII were better than those in group Ⅰ, the differences were statistically significant （P〈 0.01）. No severe adverse drug reaction were observed in both groups. Conclusion The clinical therapeutic efficacy and safety for moderate asthma treatment are determined in both two ways of the Budesonide power for inhalation and Budesonide powder for inhalation combinated with Theophylline. It is more effective and rapid im

关 键 词：哮喘 茶碱 糖皮质激素 肺功能 

分 类 号：R562.25[医药卫生—呼吸系统]